Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
70 participants
OBSERVATIONAL
2014-11-30
2015-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
All variables were collected through retrospective review of medical records of patients dermatology unit are made.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Evaluating Safety of Etanercept in Treatment of Patients With Moderate to Severe Psoriasiswith Etanercept
NCT00581165
Study Evaluating the Safety and Efficacy of Etanercept 50 mg Once Weekly in Subjects With Psoriasis
NCT00333034
Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis
NCT03358290
Study Evaluating Etanercept for the Treatment of Moderate to Severe Psoriasis
NCT00663052
Study Evaluating the Efficacy and Safety of Etanercept and Acitretin in Korean Patient With Moderate to Severe Psoriasis
NCT00936065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* PASI\> 10 and / or BSA(Body Surface Area)\> 10% and / or DLQI(Dermatology Life Quality Index)\> 10
* Over 60 years of age at the start of treatment
* Receiving etanercept at any time
* Available history in the Dermatology
Exclusion Criteria
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fundación Pública Andaluza Progreso y Salud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Enrique Herrera Ceballos, MD
Role: STUDY_DIRECTOR
H.U. Virgen de la Victoria
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital Clinic
Barcelona, Barcelona, Spain
H.U. Reina Sofía
Córdoba, Córdoba, Spain
Hospital de Andújar
Jaén, Jaén, Spain
Hospital la Paz
Madrid, Madrid, Spain
H.U. Virgen de la Victoria
Málaga, Málaga, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FPA-ETA-2014-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.